Choice of Wedge Resection for Selected T1a/bN0M0 Non-small Cell Lung Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2024 Oct 15

PMID 39406938

Authors

Zhengshui Xu

Zhenchuan Ma

Feng Zhao

Jianzhong Li

Ranran Kong

Shaomin Li

Jiantao Jiang

Huafeng Kang

Dandan Liu

Affiliations

Soon will be listed here.

Abstract

Recently, several studies have reported that the survival benefit of wedge resection might not be inferior to that of lobectomy in early-stage NSCLC patients, but there is no unified definition of the details or cutoff value. Patients with early-stage NSCLC with a tumour size ≤ 2.0 cm were chosen from the SEER database. The influence of confounding factors was minimized by 1:1 propensity score matching (PSM). Kaplan‒Meier curves and Cox proportional hazards models were used to evaluate the overall survival (OS) and lung cancer-specific survival (LCSS) of patients undergoing lobectomy and wedge resection. A total of 3891 patients with early-stage NSCLC with tumour size ≤ 2.0 cm were enrolled, of whom 2839 underwent lobectomy and 1052 underwent wedge resection. Both before and after PSM, lobectomy significantly improved OS and LCSS compared with wedge resection in the unstratified study population. In the tumour size ≤ 1 cm group, lobectomy had better OS and LCSS than wedge resection (P < 0.05) before PSM; after PSM, there was no significant difference in OS (P = 0.16) and LCSS (P = 0.17). In Grade I patients, before PSM, lobectomy was superior to wedge resection in LCSS (P = 0.038), while there was no significant difference in OS (P = 0.16); after PSM, there were no significant differences in either OS (P = 0.78) or LCSS (P = 0.11). For early-stage NSCLC patients with a tumour size ≤ 1 cm or with a tumour size ≤ 2 cm and with Grade I, there was no significant difference in survival between wedge resection and lobectomy.

References

Dai C, Shen J, Ren Y, Zhong S, Zheng H, He J . Choice of Surgical Procedure for Patients With Non-Small-Cell Lung Cancer ≤ 1 cm or > 1 to 2 cm Among Lobectomy, Segmentectomy, and Wedge Resection: A Population-Based Study. J Clin Oncol. 2016; 34(26):3175-82. DOI: 10.1200/JCO.2015.64.6729. View

Huang W, Deng H, Wu X, Xu K, Li P, Lin M . Surgical resection versus radiotherapy for clinical stage IA lung cancer ≤1 cm in size: A population-based study. Asian J Surg. 2022; 46(1):385-393. DOI: 10.1016/j.asjsur.2022.04.078. View

Inderbitzi R, Furrer M, Klaiber C, Ris H, Striffeler H, ALTHAUS U . Thoracoscopic wedge resection. Surg Endosc. 1992; 6(4):189-92. DOI: 10.1007/BF02210879. View

Bertolaccini L, Cara A, Chiari M, Diotti C, Glick N, Mohamed S . Real-world survival outcomes of wedge resection versus lobectomy for cT1a/b cN0 cM0 non-small cell lung cancer: a single center retrospective analysis. Front Oncol. 2023; 13:1226429. PMC: 10470827. DOI: 10.3389/fonc.2023.1226429. View

Asamura H, Aokage K, Yotsukura M . Wedge Resection Versus Anatomic Resection: Extent of Surgical Resection for Stage I and II Lung Cancer. Am Soc Clin Oncol Educ Book. 2017; 37:426-433. DOI: 10.1200/EDBK_179730. View

JACOBSON M, Zand L, FOX R, Lees W . A comparison of wedge and segmental resection of the lung. Thorax. 1976; 31(4):365-8. PMC: 470442. DOI: 10.1136/thx.31.4.365. View

Khullar O, Gillespie T, Nickleach D, Liu Y, Higgins K, Ramalingam S . Socioeconomic risk factors for long-term mortality after pulmonary resection for lung cancer: an analysis of more than 90,000 patients from the National Cancer Data Base. J Am Coll Surg. 2014; 220(2):156-168.e4. PMC: 4297595. DOI: 10.1016/j.jamcollsurg.2014.10.009. View

Koike T, Koike T, Yamato Y, Yoshiya K, Toyabe S . Predictive risk factors for mediastinal lymph node metastasis in clinical stage IA non-small-cell lung cancer patients. J Thorac Oncol. 2012; 7(8):1246-51. DOI: 10.1097/JTO.0b013e31825871de. View

Ding H, Song N, Zhang P, Jiang G, Wang H . Wedge resection plus adequate lymph nodes resection is comparable to lobectomy for small-sized non-small cell lung cancer. Front Oncol. 2022; 12:1022904. PMC: 9691685. DOI: 10.3389/fonc.2022.1022904. View

10.

Shen J, Zhuang W, Xu C, Jin K, Chen B, Tian D . Surgery or Non-surgical Treatment of ≤8 mm Non-small Cell Lung Cancer: A Population-Based Study. Front Surg. 2021; 8:632561. PMC: 8187794. DOI: 10.3389/fsurg.2021.632561. View

11.

Ding H, Wang H, Xu L, Song N, Jiang G . Survival and Resected Lymph Node Number During Sublobar Resection for N0 Non-Small Cell Lung Cancer 2 cm or Less. Ann Thorac Surg. 2019; 107(6):1647-1655. DOI: 10.1016/j.athoracsur.2018.12.024. View

12.

Heiden B, Eaton Jr D, Engelhardt K, Chang S, Yan Y, Patel M . Analysis of Delayed Surgical Treatment and Oncologic Outcomes in Clinical Stage I Non-Small Cell Lung Cancer. JAMA Netw Open. 2021; 4(5):e2111613. PMC: 8160592. DOI: 10.1001/jamanetworkopen.2021.11613. View

13.

Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D . Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. N Engl J Med. 2023; 388(6):489-498. PMC: 10036605. DOI: 10.1056/NEJMoa2212083. View

14.

Song W, Hou Y, Zhang J, Zhou Q . Comparison of outcomes following lobectomy, segmentectomy, and wedge resection based on pathological subtyping in patients with pN0 invasive lung adenocarcinoma ≤1 cm. Cancer Med. 2022; 11(24):4784-4795. PMC: 9761055. DOI: 10.1002/cam4.4807. View

15.

Zhang Y, Sun Y, Chen H . Effect of tumor size on prognosis of node-negative lung cancer with sufficient lymph node examination and no disease extension. Onco Targets Ther. 2016; 9:649-53. PMC: 4751902. DOI: 10.2147/OTT.S98509. View

16.

Thomas P . Lymph node dissection during sublobar resection: why, when and how?. J Thorac Dis. 2018; 10(Suppl 10):S1145-S1150. PMC: 5949390. DOI: 10.21037/jtd.2018.01.30. View

17.

Wolf A, Richards W, Jaklitsch M, Gill R, Chirieac L, Colson Y . Lobectomy versus sublobar resection for small (2 cm or less) non-small cell lung cancers. Ann Thorac Surg. 2011; 92(5):1819-23. DOI: 10.1016/j.athoracsur.2011.06.099. View

18.

Rami-Porta R, Tsuboi M . Sublobar resection for lung cancer. Eur Respir J. 2009; 33(2):426-35. DOI: 10.1183/09031936.00099808. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Schuchert M, Normolle D, Awais O, Pennathur A, Wilson D, Luketich J . Factors influencing recurrence following anatomic lung resection for clinical stage I non-small cell lung cancer. Lung Cancer. 2019; 128:145-151. PMC: 7507791. DOI: 10.1016/j.lungcan.2018.12.026. View